Bangladesh may get 12,792,000 doses of Covid-19 vaccines in first half through the World Health Organization's (WHO) under COVAX facility.
It has been indicated at COVAX's interim distribution forecast, published on February 3.
Bangladesh will get Oxford/Astrazeneca vaccine manufactured by Serum Inistitute of India.
The amount of the doses are in proportion to population size.
According to the document, Pakistan will be getting 17.2 million doses, India 79.1 million, Nigeria 16 million, Indonesia 13.7 million, Bangladesh 12.8 million and Brazil 10.6 million.
The Coalition for Epidemic Preparedness Innovations (CEPI), Gavi, the Vaccine Alliance, and the World Health Organisation (WHO), as co-leads of the COVAX initiative for equitable global access to COVID-19 vaccines, published COVAX's first interim COVID-19 vaccine distribution forecast.
This document contains information on indicative distribution of 240 million doses of the AstraZeneca/Oxford vaccine, licensed to Serum Institute of India (SII) – hereinafter "AZ/SII" and 96 million doses of the AstraZeneca/Oxford vaccine, under the advance purchase agreement between Gavi, the Vaccine Alliance and AstraZeneca – hereinafter "AZ", for Q1 & Q2 2021.
It also contains an overview of exceptional first round allocation of 1.2 million doses of the WHO Emergency Use Listing (EUL)-approved Pfizer-BioNTech vaccine – hereinafter "Pfizer-BioNTech", for Q1 2021. It is important to note additional doses of both these products will be available to the COVAX Facility in 2021.